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ABSTRACT
Background: Persons with diabetes mellitus (DM) exhibit a higher rate of 
depressive illness than does the general US population. Despite this finding, previ-
ous research has documented a low rate of diagnosis and/or treatment with antidepres-
sant pharmacotherapy among persons with DM. 
Objective: The aim of this study was to examine the current rate of diagnosis 
of depression and use of antidepressant pharmacotherapy among persons with DM. 
Results: We examined data from the 2005 US National Ambulatory Medical 
Care Survey. In 2005, there were an estimated 35,345,845 persons with an office-
based visit for DM and, of these, 3,823,508 (10.8%) had a concomitant diagnosis of 
depression. Within this subset, 1,830,620 (47.9%) were prescribed antidepressant 
pharmacotherapy.
Conclusion: Our findings serve to quantify the prevalence of a diagnosis of 
depression and use of antidepressant pharmacotherapy for its treatment among persons 
with DM in the United States. (Curr Ther Res Clin Exp. 2009;70:472–476) © 2009 
Excerpta Medica Inc.
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INTRODUCTION
Diabetes mellitus (DM) is a major cause of morbidity, mortality, and economic expense 
worldwide.1 It is estimated that by the year 2050, the global prevalence of DM 
will increase by 165% from that of the year 2000.1,2 In the United States alone, the 
number of cases is projected to reach 48 million by that year.2 In 2002, direct and 
indirect expenditures for DM in the United States were estimated to exceed $132 bil-
lion.3 Recent evidence suggests that persons with DM exhibit a higher rate of depressive 
illness than does the general population in the United States.4–6 Despite these find-
ings, previous research from a decade ago found a low prevalence of both a diagnosis 
of depression and of treatment with antidepressant pharmacotherapy among persons 
with DM.7,8 Given the greater awareness of the interface between DM and depression 
since the late 1990s,4,5 we hypothesized an increase in the prevalence of a diagnosis 
of depression and of treatment with antidepressant pharmacotherapy among persons 
with DM. The aim of this research was to examine the prevalence of a diagnosis 
of depression and the use of antidepressant pharmacotherapy among persons with 
DM.
MATERIALS AND METHODS
We examined data from the 2005 US National Ambulatory Medical Care Survey 
(NAMCS).9 The NAMCS is a national probability sample designed and conducted by 
the National Center for Health Statistics of the US Centers for Disease Control and 
Prevention. Data were collected by the US Bureau of the Census. Our objectives were 
to discern the following: (1) the characteristics of ambulatory patients aged ≥20 years 
having an office-based physician–patient encounter (visit) for DM (International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 250.00–
250.93); (2) the characteristics of the subset of ambulatory patients having an office-
based visit for DM with a concomitant diagnosis of depression (ICD-9-CM codes 
296.2–296.36, 300.4, or 311); and (3) the extent of use of antidepressant pharmaco-
therapy (US National Drug Code category number 0630).10
Statistical Analyses
Analyses were performed using SAS software version 9.1.3 (SAS Institute Inc., 
Cary, North Carolina).
RESULTS
In 2005, there were an estimated 35,345,845 persons who had an office-based visit 
for DM; of these, a subset of 3,823,508 patients (10.8%) had a concomitant diagnosis 
of depression (Table). Within this subset, 1,830,620 patients (47.9%) were pre-
scribed antidepressant pharmacotherapy (eg, tricyclic antidepressants, selective sero-
tonin reuptake inhibitors). A majority of persons with DM and a majority within the 
subset with a diagnosis of depression were female (52.8% and 62.8%, respectively) 
and non-Hispanic whites (76.0% and 84.2%). A majority of patients with DM and 
those in the subset were treated by their primary care physician (73.5% and 81.0%), 
while the reporting physician was in general/family practice (34.4% and 46.3%) or 
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internal medicine (33.9% and 27.7%). Comorbid illnesses occurred more frequently 
in patients with DM and depression than in patients with DM alone, as evidenced by 
a higher rate of hypertension (73.3% vs 64.1%, respectively), hyperlipidemia (70.7% 
vs 46.3%), and obesity (40.3% vs 20.5%), among other illnesses (Table).
DISCUSSION
Previous research using the NAMCS covering the time from 1990 through 1995 
found that only 1.25% of patients with DM had a recorded diagnosis of depression 
Table.  Demographic and clinical characteristics of patients aged ≥20 years with a diag-
nosis of diabetes mellitus and patients with a diagnosis of diabetes mellitus and 
depression using data for office-based visits in the United States in 2005.9 Data 
are number (%) of visits.
  Diabetes Mellitus 
Characteristic Diabetes Mellitus and Depression
Diagnosis of diabetes mellitus*   35,345,845 (100) –
Diagnosis of depression† 3,823,508 (10.8) 3,823,508 (100)
Prescribed antidepressant‡ – 1,830,620 (47.9)
Age, y
  20–64 17,266,367 (48.8) 2,009,061 (52.5)
  ≥65 18,079,478 (51.2) 1,814,447 (47.5)
Sex
  Female 18,672,363 (52.8) 2,400,653 (62.8)
  Male 16,673,482 (47.2) 1,422,855 (37.2)
Race
  White 26,874,263 (76.0) 3,221,126 (84.2)
  Nonwhite 8,471,582 (24.0) 602,382 (15.8)
Treated by primary physician 25,965,090 (73.5) 3,097,690 (81.0)
Reporting physician
  General/family practice 12,162,735 (34.4) 1,771,050 (46.3)
  Internal medicine 11,964,755 (33.9) 1,057,960 (27.7)
  All others 11,218,355 (31.7) 994,498 (26.0)
Concomitant chronic disease
  Hypertension 22,654,472 (64.1) 2,804,098 (73.3)
  Hyperlipidemia 16,367,100 (46.3) 2,702,057 (70.7)
  Obesity 7,253,707 (20.5) 1,540,799 (40.3)
  Ischemic heart disease 3,726,667 (10.5) 813,337 (21.3)
  Chronic renal failure 2,292,231 (6.5) 405,434 (10.6)
  Cerebrovascular disease 1,610,670 (4.6) 380,883 (10.0)
  Congestive heart failure 1,395,726 (3.9) 297,523 (7.8) 
* International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 
250.00–250.93.
†ICD-9-CM codes 296.2–296.36, 300.4, or 311.
‡US National Drug Code category number 0630. 
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and that <3% of these patients were prescribed antidepressant pharmacotherapy.8 
Our findings indicate that by 2005, there had been important increases in the rate of 
diagnosing depression in patients with DM and in the rate of prescribing antidepres-
sant pharmacotherapy among these patients. Previous research found a greater likeli-
hood of the development of depression in persons with DM who exhibited comorbid 
illnesses.5,6 Depression in patients with DM has been associated with inadequate gly-
cemic control and significant physical decline.5,6 Additional research is needed to 
elucidate the factors affecting the rates of diagnosing depression and of prescribing 
antidepressant pharmacotherapy among persons with DM.
Limitations
Our study has several limitations inherent in the NAMCS. The NAMCS docu-
ments the diagnostic codes chosen and recorded by individual physicians rather than 
results stemming from a standardized and independent clinical appraisal. Neither 
patient symptomatology nor illness severity is recorded in the NAMCS, therefore 
negating the chance to investigate the mediating influence these factors have on a 
physician’s conclusion relative to a diagnosis of depression and/or decisions associated 
with the prescribing of antidepressant pharmacotherapy. The NAMCS only provides 
data regarding the name of each medication prescribed during a specific office visit 
or continued from a prior visit, without any indication of the dosage, regimen, sub-
sequent experience with adverse events, or length of use.11
CONCLUSION
Our findings serve to quantify the prevalence of a diagnosis of depression and use of 
antidepressant pharmacotherapy for its treatment among persons with DM in the 
United States.
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